Literature DB >> 20096645

Early insulin sensitivity after restrictive bariatric surgery, inconsistency between HOMA-IR and steady-state plasma glucose levels.

Francois M H van Dielen1, Jeroen Nijhuis, Sander S M Rensen, Nicolaas C Schaper, Janneke Wiebolt, Afra Koks, Fred J Prakken, Wim A Buurman, Jan Willem M Greve.   

Abstract

BACKGROUND: The low-grade inflammatory condition present in morbid obesity is thought to play a causative role in the pathophysiology of insulin resistance (IR). Bariatric surgery fails to improve this inflammatory condition during the first months after surgery. Considering the close relation between inflammation and IR, we conducted a study in which insulin sensitivity was measured during the first months after bariatric surgery. Different methods to measure IR shortly after bariatric surgery have given inconsistent data. For example, the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) levels have been reported to decrease rapidly after bariatric surgery, although clamp techniques have shown sustained insulin resistance. In the present study, we evaluated the use of steady-state plasma glucose (SSPG) levels to assess insulin sensitivity 2 months after bariatric surgery.
METHODS: Insulin sensitivity was measured using HOMA-IR and SSPG levels in 11 subjects before surgery and at 26% excess weight loss (approximately 2 months after restrictive bariatric surgery).
RESULTS: The SSPG levels after 26% excess weight loss did not differ from the SSPG levels before surgery (14.3 +/- 5.4 versus 14.4 +/- 2.7 mmol/L). In contrast, the HOMA-IR values had decreased significantly (3.59 +/- 1.99 versus 2.09 +/- 1.02).
CONCLUSION: During the first months after restrictive bariatric surgery, we observed a discrepancy between the HOMA-IR and SSPG levels. In contrast to the HOMA-IR values, the SSPG levels had not improved, which could be explained by the ongoing inflammatory state after bariatric surgery. These results suggest that during the first months after restrictive bariatric surgery, HOMA-IR might not be an adequate marker of insulin sensitivity. Copyright 2010 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20096645     DOI: 10.1016/j.soard.2009.11.011

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  5 in total

1.  Evaluation of Persistent Efficacy of Diabetes Remission and Decline of Cardiovascular Risk After Laparoscopic Sleeve Gastrectomy: a Preliminary 1-Year Study.

Authors:  Yu-Min Huang; Weu Wang; Shu-Chen Wei; Pei-Fen Lee; Yi-Chiang Hsu; Wan-Ling Tu; Hsin-Hung Chen
Journal:  Obes Surg       Date:  2022-07-23       Impact factor: 3.479

2.  SPINA Carb: a simple mathematical model supporting fast in-vivo estimation of insulin sensitivity and beta cell function.

Authors:  Bernhard O Boehm; Nihal Thomas; Johannes W Dietrich; Riddhi Dasgupta; Shajith Anoop; Felix Jebasingh; Mathews E Kurian; Mercy Inbakumari
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

Review 3.  Effects of bariatric surgery on glucose homeostasis and type 2 diabetes.

Authors:  David Bradley; Faidon Magkos; Samuel Klein
Journal:  Gastroenterology       Date:  2012-08-08       Impact factor: 22.682

4.  Duodenal-jejunal bypass surgery up-regulates the expression of the hepatic insulin signaling proteins and the key regulatory enzymes of intestinal gluconeogenesis in diabetic Goto-Kakizaki rats.

Authors:  Dong Sun; Kexin Wang; Zhibo Yan; Guangyong Zhang; Shaozhuang Liu; Fengjun Liu; Chunxiao Hu; Sanyuan Hu
Journal:  Obes Surg       Date:  2013-11       Impact factor: 4.129

5.  Hormonal responses and test meal intake among obese teenagers before and after laparoscopic adjustable gastric banding.

Authors:  Robyn Sysko; Michael J Devlin; Janet Schebendach; Marian Tanofsky-Kraff; Ellen Zimmerli; Judith Korner; Jack A Yanovski; Jeffrey L Zitsman; B Timothy Walsh
Journal:  Am J Clin Nutr       Date:  2013-08-28       Impact factor: 7.045

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.